SG11201706258WA - Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders - Google Patents

Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders

Info

Publication number
SG11201706258WA
SG11201706258WA SG11201706258WA SG11201706258WA SG11201706258WA SG 11201706258W A SG11201706258W A SG 11201706258WA SG 11201706258W A SG11201706258W A SG 11201706258WA SG 11201706258W A SG11201706258W A SG 11201706258WA SG 11201706258W A SG11201706258W A SG 11201706258WA
Authority
SG
Singapore
Prior art keywords
cd40l
disorders
methods
treating
related diseases
Prior art date
Application number
SG11201706258WA
Inventor
John M Lincecum
Bingbing Jiang
Steven N Perrin
Alan Gill
Cynthia A Gill
Fernando G Vieira
Original Assignee
Als Therapy Dev Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Als Therapy Dev Inst filed Critical Als Therapy Dev Inst
Publication of SG11201706258WA publication Critical patent/SG11201706258WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
SG11201706258WA 2015-02-03 2016-02-02 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders SG11201706258WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562111261P 2015-02-03 2015-02-03
PCT/US2016/016165 WO2016126702A1 (en) 2015-02-03 2016-02-02 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders

Publications (1)

Publication Number Publication Date
SG11201706258WA true SG11201706258WA (en) 2017-08-30

Family

ID=56564599

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912752QA SG10201912752QA (en) 2015-02-03 2016-02-02 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
SG11201706258WA SG11201706258WA (en) 2015-02-03 2016-02-02 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201912752QA SG10201912752QA (en) 2015-02-03 2016-02-02 Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders

Country Status (15)

Country Link
US (5) US10106618B2 (en)
EP (2) EP4071175A1 (en)
JP (3) JP6797810B2 (en)
KR (1) KR20170108024A (en)
CN (2) CN108064168B (en)
AU (2) AU2016215505B8 (en)
CA (1) CA2974135A1 (en)
DK (1) DK3253412T3 (en)
GB (1) GB2552429A (en)
IL (2) IL253571B (en)
MA (1) MA41459A (en)
MX (2) MX2017009694A (en)
RU (1) RU2727646C2 (en)
SG (2) SG10201912752QA (en)
WO (1) WO2016126702A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6170840B2 (en) 2011-03-11 2017-07-26 ベス イスラエル デアコネス メディカル センター インコーポレイテッド Anti-CD40 antibody and use thereof
MA41459A (en) 2015-02-03 2017-12-12 Als Therapy Development Inst ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS
PT3307322T (en) 2015-09-04 2021-04-23 Primatope Therapeutics Inc Humanized anti-cd40 antibodies and uses thereof
GB2578037A (en) * 2017-05-24 2020-04-15 Als Therapy Development Inst Therapeutic anti-CD40 ligand antibodies
WO2021001458A1 (en) * 2019-07-01 2021-01-07 Tonix Pharma Holdings Limited Anti-cd154 antibodies and uses thereof
WO2021006604A1 (en) * 2019-07-08 2021-01-14 주식회사 프로젠 Novel fusion protein and use of same
KR20210095781A (en) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety
WO2022150452A1 (en) * 2021-01-06 2022-07-14 Seth Lederman Methods of inducing immune tolerance with modified anti-cd154 antibodies
JP2024505600A (en) 2021-02-03 2024-02-06 モーツァルト セラピューティクス， インコーポレイテッド Binders and how to use them
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
CN114149508B (en) * 2021-11-25 2023-04-28 苏州普乐康医药科技有限公司 Fusion protein combined with CD40L and application thereof
KR20230108156A (en) * 2022-01-10 2023-07-18 주식회사 금호에이치티 Antibody specifically binding to CD40L and use thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5962406A (en) 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
ATE188487T1 (en) 1993-09-02 2000-01-15 Dartmouth College ANTI-GP39 ANTIBODIES AND USES THEREOF
US5833987A (en) 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
EE9900273A (en) 1997-01-10 2000-02-15 Biogen, Incorporated Treatment of lupus nephritis with anti-CD40L compounds
HUP0003392A3 (en) 1997-05-17 2002-09-30 Biogen Idec Ma Inc Cambridge Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
KR20010072564A (en) 1998-04-03 2001-07-31 존 에프. 카바나프 USE OF ANTI-gp39 ANTIBODIES FOR TREATMENT AND/OR REVERSAL OF LUPUS AND ASSOCIATED KIDNEY DISEASE
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
RU2305561C2 (en) 1999-11-08 2007-09-10 Байоджен Айдек Инк. Treatment of b-cellular malignant tumors using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or by chemotherapy and radiotherapy
EP1253942A4 (en) 2000-02-01 2004-06-16 Tanox Inc Cd40-binding apc-activating molecules
GB0006398D0 (en) 2000-03-16 2000-05-03 Novartis Ag Organic compounds
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
CA2408691A1 (en) * 2000-05-12 2001-11-22 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
MXPA03000306A (en) 2000-07-12 2004-04-05 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications.
AU8867501A (en) 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
EP1399435A2 (en) 2000-09-01 2004-03-24 Biogen, Inc. Pyridine derivatives useful as cd40:cd154 binding interruptors and use thereof to treat immunological complications
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
WO2004037204A2 (en) 2002-10-25 2004-05-06 University Of South Florida Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
DK1639014T3 (en) 2003-06-13 2011-01-17 Biogen Idec Inc Aglycosyl anti-CD154 (CD40 ligand) antibodies and uses thereof
EP1646654A1 (en) 2003-07-08 2006-04-19 Genesto A/S BINDING MEMBER TOWARDS PNEUMOCOCCUS SURFACE ADHESIN A PROTEIN (PsaA)
NZ580688A (en) 2003-07-26 2012-03-30 Biogen Idec Inc Method of designing altered antibodies having improved antigen-binding affinity
CA2536408A1 (en) * 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US20170166655A1 (en) 2004-03-26 2017-06-15 Xencor, Inc. Novel immunoglobulin variants
KR20070047327A (en) 2004-07-26 2007-05-04 비오겐 아이덱 엠에이 아이엔씨. Anti-cd154 antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006138316A2 (en) 2005-06-14 2006-12-28 Biogen Idec Ma Inc. Methods for delivering molecules to the central nervous system
WO2007059332A2 (en) 2005-11-17 2007-05-24 Biogen Idec Ma Inc. Platelet aggregation assays
EP1962886B2 (en) 2005-12-20 2022-02-23 Bristol-Myers Squibb Company Stable protein formulations
US7647438B1 (en) * 2006-05-09 2010-01-12 Integrated Device Technology, Inc. Binary base address sorting method and device with shift vector
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
KR101605908B1 (en) 2007-03-22 2016-03-23 바이오젠 엠에이 인코포레이티드 Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
MX2009012343A (en) 2007-05-14 2010-02-10 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto.
GB0815788D0 (en) 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
US9044459B2 (en) 2008-12-05 2015-06-02 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
US8435514B2 (en) 2008-12-05 2013-05-07 Als Therapy Development Institute Method for the treatment of neurodegenerative diseases
AU2010206681A1 (en) * 2009-01-23 2011-09-01 Biogen Idec Ma Inc. Stabilized Fc polypeptides with reduced effector function and methods of use
WO2012103218A1 (en) 2011-01-25 2012-08-02 University Of South Florida A transgenic model of alzheimer's disease
WO2012130831A1 (en) 2011-03-29 2012-10-04 Roche Glycart Ag Antibody fc variants
US9028826B2 (en) 2011-04-04 2015-05-12 The Trustees Of Dartmouth College Methods of immune therapy with anti-CD154 antibodies having impaired FcR binding and/or complement binding properties
WO2012138768A2 (en) 2011-04-04 2012-10-11 Trustees Of Dartmouth College Anti-cd154 antibodies having impaired fcr binding and/or complement binding properties and the use thereof in immune therapies
PT2699601T (en) * 2011-04-21 2018-04-05 Domantis Ltd Antibody polypeptides that antagonize cd40
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
TW201326209A (en) * 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance
SG10201610288TA (en) 2011-10-13 2017-02-27 Bristol Myers Squibb Co Antibody polypeptides that antagonize cd40l
SG11201405968SA (en) 2012-05-11 2014-11-27 Medimmune Llc Ctla-4 variants
EP2909303B1 (en) 2012-10-18 2020-04-15 Yongxin Zhang Bioreactor system and methods for alternative cell culture between static and dynamic
AU2014250434B2 (en) * 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
SG11201606521VA (en) 2014-03-19 2016-10-28 Bristol Myers Squibb Co Methods of treating transplant rejection using a domain antibody directed against cd40l
WO2015164595A1 (en) 2014-04-25 2015-10-29 Bristol-Myers Squibb Company Use of ctla4 compound for achieving drug-free remission in subjects with early ra
WO2016028810A1 (en) 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
MA41459A (en) * 2015-02-03 2017-12-12 Als Therapy Development Inst ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS
GB2578037A (en) 2017-05-24 2020-04-15 Als Therapy Development Inst Therapeutic anti-CD40 ligand antibodies

Also Published As

Publication number Publication date
JP2021054826A (en) 2021-04-08
US20240043549A1 (en) 2024-02-08
EP3253412A4 (en) 2018-08-01
CN108064168B (en) 2021-10-26
GB2552429A (en) 2018-01-24
EP3253412A1 (en) 2017-12-13
AU2022200323A1 (en) 2022-02-17
US20190092868A1 (en) 2019-03-28
GB201713871D0 (en) 2017-10-11
IL253571B (en) 2022-04-01
JP6797810B2 (en) 2020-12-09
RU2727646C2 (en) 2020-07-22
KR20170108024A (en) 2017-09-26
RU2017126997A3 (en) 2019-09-19
MX2017009694A (en) 2018-03-15
EP3253412B1 (en) 2022-03-23
SG10201912752QA (en) 2020-02-27
AU2016215505B8 (en) 2021-11-11
CN108064168A (en) 2018-05-22
IL253571A0 (en) 2017-09-28
US11692040B2 (en) 2023-07-04
AU2016215505A2 (en) 2019-01-24
CA2974135A1 (en) 2016-08-11
US20210269538A1 (en) 2021-09-02
MA41459A (en) 2017-12-12
MX2022005655A (en) 2022-06-29
US10683356B2 (en) 2020-06-16
US10106618B2 (en) 2018-10-23
RU2017126997A (en) 2019-03-04
AU2016215505A1 (en) 2017-07-27
DK3253412T3 (en) 2022-05-23
EP4071175A1 (en) 2022-10-12
US11014990B2 (en) 2021-05-25
US20170342158A1 (en) 2017-11-30
US20200277391A1 (en) 2020-09-03
AU2016215505B2 (en) 2021-10-28
IL287823A (en) 2022-01-01
CN114195895A (en) 2022-03-18
WO2016126702A1 (en) 2016-08-11
JP2018510132A (en) 2018-04-12
JP2023036717A (en) 2023-03-14

Similar Documents

Publication Publication Date Title
IL287823A (en) Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
HK1252741A1 (en) Compositions and methods for treating neurological disorders
HK1231417A1 (en) Compounds for treating ophthalmic diseases and disorders
IL285151A (en) Methods of treating fgf21-associated disorders
HK1259336A1 (en) Methods for treating myeloproliferative disorders
IL279308A (en) Methods for treating hepcidin-mediated disorders
HK1256036A1 (en) Methods for treating myeloproliferative disorders
IL269174A (en) Methods for treating complement-mediated diseases and disorders
ZA201702214B (en) Methods of using interleukin-10 for treating diseases and disorders
PT3119911T (en) Methods for treating neurological disorders
SG10201913400QA (en) Methods for treating lung disorders
HK1245127A1 (en) Methods and compositions for treating brain diseases
IL250114B (en) Methods and compositions for treating hiv-related disorders
IL258515A (en) Methods of treatment using anti-il-17a/f antibodies
IL252904A0 (en) Methods and agents for treating disease
HK1245671A1 (en) Methods of using interleukin-10 for treating diseases and disorders
HK1243937A1 (en) Methods of treating diseases
HK1244782A1 (en) Compositions and methods for treating diseases and conditions
ZA202001927B (en) Method for treating tnf alpha-related diseases
GB201500555D0 (en) Method and device for the treatment of diseases